Inclusion Criteria:

- • Patients must have a primary invasive cutaneous melanoma of Breslow thickness
greater than 1 millimetre as determined by diagnostic biopsy (narrow excision,
incision or punch biopsy) and subsequent histopathological analysis.

- Have a primary melanoma that is cutaneous (including head, neck, trunk,
extremity, scalp, palm, sole).

- Randomisation must take place within 90 days of original diagnosis

- Patients must be 18 years or over at time of consent.

- Patient must be able to give informed consent.

- Life expectancy of at least 10 years from the time of diagnosis, not considering
the melanoma in question, as determined by the PI.

- A survivor of prior cancer is eligible provided that ALL of the following
criteria are met and documented:

- The patient has undergone potentially curative therapy for all prior
malignancies,

- There has been no evidence of recurrence of any prior malignancies for at
least FIVE years (except for successfully treated cervical or non-melanoma
skin cancer with no evidence of recurrence), and

- The patient is deemed by their treating physician to be at low risk of
recurrence from previous malignancies

- The patient agrees to be followed up at an investigating centre for 10 years.

Exclusion Criteria:

- • Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown
malignant potential'.

- Patient has already undergone wide local excision at the site of the primary
index lesion.

- Patient has already undergone a local flap reconstruction of the defect after
excision of the primary and determination of an accurate excision margin is
impossible.

- History of previous or concurrent (i.e., second primary) invasive melanoma.

- Melanoma located distal to the metacarpophalangeal joint, on the tip of the
nose, the eyelids or on the ear.

- Primary melanoma of the eye, ears, mucous membranes or internal viscera.

- Physical, clinical, radiographic or pathologic evidence of satellite,
in-transit, regional, or distant metastatic disease.

- Patient has undergone surgery on a separate occasion to clear the lymph nodes of
the probable draining lymphatic field, including sentinel lymph node biopsy, of
the index melanoma.

- Any additional solid tumor or hematologic malignancy during the past 5 years
except T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or
uterine cervical cancer.

- Skin grafts, tissue transfers or flaps that have the potential to alter the
lymphatic drainage

- Organic brain syndrome or significant impairment of basal cognitive function or
any psychiatric disorder that might preclude participation in the full protocol,
or be exacerbated by therapy (e.g., severe depression).

- Melanoma-related operative procedures not corresponding to criteria described in
the protocol.

- Primary or secondary immune deficiencies or known significant autoimmune
disease.

- History of organ transplantation.

- Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at
any time during study participation or within 6 months prior to enrolment.